ARQT Strangle Strategy
ARQT (Arcutis Biotherapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT (Arcutis Biotherapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.71B, a beta of 1.59 versus the broader market, a 52-week range of 12.72-31.77, average daily share volume of 1.5M, a public-listing history dating back to 2020, approximately 342 full-time employees. These structural characteristics shape how ARQT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.59 indicates ARQT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on ARQT?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ARQT snapshot
As of May 15, 2026, spot at $21.48, ATM IV 53.60%, IV rank 18.78%, expected move 15.37%. The strangle on ARQT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ARQT specifically: ARQT IV at 53.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a ARQT strangle, with a market-implied 1-standard-deviation move of approximately 15.37% (roughly $3.30 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ARQT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ARQT should anchor to the underlying notional of $21.48 per share and to the trader's directional view on ARQT stock.
ARQT strangle setup
The ARQT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ARQT near $21.48, the first option leg uses a $22.55 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ARQT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ARQT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $22.55 | N/A |
| Buy 1 | Put | $20.41 | N/A |
ARQT strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ARQT strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ARQT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ARQT
Strangles on ARQT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARQT chain.
ARQT thesis for this strangle
The market-implied 1-standard-deviation range for ARQT extends from approximately $18.18 on the downside to $24.78 on the upside. A ARQT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ARQT IV rank near 18.78% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ARQT at 53.60%. As a Healthcare name, ARQT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ARQT-specific events.
ARQT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ARQT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ARQT alongside the broader basket even when ARQT-specific fundamentals are unchanged. Always rebuild the position from current ARQT chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ARQT?
- A strangle on ARQT is the strangle strategy applied to ARQT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ARQT stock trading near $21.48, the strikes shown on this page are snapped to the nearest listed ARQT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ARQT strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ARQT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 53.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ARQT strangle?
- The breakeven for the ARQT strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ARQT market-implied 1-standard-deviation expected move is approximately 15.37%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ARQT?
- Strangles on ARQT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARQT chain.
- How does current ARQT implied volatility affect this strangle?
- ARQT ATM IV is at 53.60% with IV rank near 18.78%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.